FDA colorectal cancer endpoints meeting
Executive Summary
FDA will hold a public workshop on clinical trial endpoints for colorectal cancer Nov. 12. 1Draft questions for discussion include whether an increase in disease-free survival compared to standard therapy could be regular and/or accelerated approval standard in an adjuvant setting. For the first-line treatment setting, "is survival the only acceptable endpoint for supporting the approval of drugs for first-line treatment of colon cancer?" FDA asks. Issues identified at the workshop will be further discussed at a meeting of FDA's Oncologic Drugs Advisory Committee and "thereafter will be detailed in FDA guidance documents," the 2workshop announcement says. The meeting will be held from 8 a.m.-5 p.m. at the Marriott Wardman Park Hotel in Washington, D.C...
You may also be interested in...
Erbitux advisory committee in December?
FDA's Oncologic Drugs Advisory Committee is tentatively scheduled to meet Dec. 16 and 17, with Bristol/ImClone's colorectal cancer agent Erbitux BLA one potential meeting topic. During an Oct. 23 conference call, Bristol noted that Erbitux has cleared one milestone already: FDA has formally accepted the application for filing this time around. The user fee action deadline is Feb. 14. Bristol is not anticipating any impact on the review from a Nov. 12 workshop on colorectal cancer endpoints (1"The Pink Sheet" Oct. 20, 2003, In Brief)...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.